Rogers

Yahoo Finance • 4 days ago

Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

F. Hoffmann-La Roche Ltd The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences cluster The Institute of Human Biology (IHB) enables scientists to pioneer h... Full story

Yahoo Finance • 5 days ago

Why The Roche Holding (SWX:ROG) Narrative Is Shifting On Mixed Pipeline Signals And Valuation

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Roche Holding’s updated fair value estimate has shifted from CHF 358.45 to CHF 363.47, a modest mo... Full story

Yahoo Finance • 9 days ago

Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation

Roche's Ionify® steroid assays join its Vitamin D Total test as the latest mass spectrometry tests to receive CLIA 'moderate complexity' classification. The expanded steroid menu brings the sensitivity and specificity of mass spectrometry... Full story

Yahoo Finance • 10 days ago

Trending tickers: Nvidia, Roche, Travis Perkins, Wickes and Close Brothers

Markets had a mixed start to trading on Tuesday, as Iran continued to attack key energy infrastructure in the ongoing conflict with Israel and the US. The UK’s FTSE 100 (^FTSE) advanced 0.3%, while Germany’s DAX (^GDAXI) fell about 0.3% a... Full story

Yahoo Finance • 11 days ago

Assessing Roche (SWX:ROG) Valuation After Recent Share Price Volatility And Obesity Drug Pipeline Update

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Roche Holding: Recent Moves and What They Mean for Investors Roch... Full story

Yahoo Finance • 11 days ago

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

F. Hoffmann-La Roche Ltd With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational infrastructure su... Full story

Yahoo Finance • 11 days ago

ASUS TUF Gaming A14 Packs Big Power into a Portable 14-Inch Design, Now in Canada

KEY POINTS Game and create with the FA401GM: Next-gen gaming and creation with NVIDIA® GeForce RTX™ 5060 Laptop GPU and AMD Ryzen™ AI 9 465Serious power and efficiency with the FA401EA: The AMD Ryzen™ AI Max+ 392 with Radeon™ 8060S Graphi... Full story

Yahoo Finance • 12 days ago

Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable and accessible option to rapidly differe... Full story

Yahoo Finance • 17 days ago

Roche's Breast Cancer Drug Falls Short In Phase 3 Study

Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial included patients with oestrogen recepto... Full story

Yahoo Finance • 17 days ago

Roche Annual General Meeting 2026

F. Hoffmann-La Roche Ltd Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 39th consecutive dividen... Full story

Yahoo Finance • 19 days ago

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was well tolerated and advers... Full story

Yahoo Finance • 19 days ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

F. Hoffmann-La Roche Ltd persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was... Full story

Yahoo Finance • 20 days ago

Roche Obesity Trial Success Sparks Fresh Look At Valuation And Pipeline

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Roche Holding (SWX:ROG) reported positive Phase II results from its ZUPREME-1 trial of petrelintide in obesity. The study s... Full story

Yahoo Finance • 22 days ago

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

– Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability – – At the maximally effective dose, there were no cases of vomiting and no t... Full story

Yahoo Finance • 22 days ago

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability At the maximally effective dose, there were no cases o... Full story

Yahoo Finance • 22 days ago

Is Roche Holding (SWX:ROG) Still Attractively Priced After Strong Three Year Share Gains?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether Roche Holding's current share price reflects its true worth, this article will walk through the numbe... Full story

Yahoo Finance • 23 days ago

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.1 Majority of respondents say that constantly planning around blood glucose l... Full story

Yahoo Finance • 24 days ago

Roche’s Fenebrutinib MS Results Test Valuation And Growth Expectations

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Roche Holding (SWX:ROG) reported that its investigational MS treatment fenebrutinib met key goals in pivotal Phase III... Full story

Yahoo Finance • 25 days ago

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story

Yahoo Finance • 26 days ago

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction -... Full story